Skip to main content

Table 4 Mean annual OI prevalence (per 1000) in a cohort of HIV positive individuals before and after HAART in Uganda

From: Trends in prevalence of selected opportunistic infections associated with HIV/AIDS in Uganda

 

Before HAART

Early HAART

Late HAART

 

OI

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

X 2 trend (p-value)

Cryptococcal meningitis

5.5

5.4

2.5

3.3

2.7

2.7

1.6

1.2

4.0

1.3

1.3

0.23

1.79 (0.1807)

% change

-

0

−54

+32

−18

0

−41

−25

+233

−67

0

−82

 

Mycobacterium tuberculosis

76.9

45.5

29.3

16.2

9.6

13.2

9.0

10.9

9.1

7.4

6.6

11.0

157.38 (<0.0001)

% change

-

−41

−36

−45

−41

+37

−32

+21

−16

−19

−11

+67

 

Herpes zoster

13.4

13.9

11.5

9.1

7.6

10.0

5.1

5.0

3.8

3.7

3.7

3.3

13.67 (0.0002)

% change

-

+4

−14

−25

11

+37

−54

2

−24

−20

0

−11

 

Oral candida

172.7

106.4

83.1

32.3

26.5

20.0

17.0

12.0

12.6

15.4

8.7

6.7

458.20 (<0.0001)

% change

-

−38.7

−20

−62

−16

−26

−10

−33

+8

−23

−37

−20

 

Genital ulcer(HSV-2)

15.1

18.2

17.6

12.3

9.3

12.0

11.2

8.1

9.2

7.2

7.7

8.9

8.8 (0.0029)

% change

-

+21

3.3

−33

−17

+20

−8

27

+25

−20

−12.5

+43

 
  1. Key: HAART = Highly active antiretroviral therapy; % = percent; HSV-2 = Herpes simplex virus type2.